Adlai Nortye Ltd (ANL): Price-to-Revenue Ratio

Brandmark of Adlai Nortye Ltd. (ANL)

Adlai Nortye Ltd. (ANL) develops advanced drug combinations to combat resistant tumors, leveraging a flexible network of regional supply hubs and a global network of clinics across Europe, China, and the US. The market capitalization-to-revenue ratio confirms these fundamental successes, with the current parameter equal to 34.50, helping investors assess the business's market value relative to its turnover.

P/S Multiple: Adlai Nortye Limited (ANL) for 04/13/2026 - 11/16/2026

Metric breakdowns and analytics for Adlai Nortye Limited (ANL)

- stock price and consensus target price:
- stock exchange capitalization data:
Fundamental company analysis:ANL - Adlai Nortye Ltd.
Finished products of Adlai Nortye Ltd

Adlai Nortye Ltd. (ANL) operates a high-risk oncology development business without commercial sales. In the absence of operating profit, the market capitalization-to-revenue ratio reflects a speculative valuation of future clinical trial successes. This multiple compares the total equity value with the volume of incoming partner contributions, measuring the premium for innovation potential. High indicator values signal inflated market expectations relative to the issuer's current financial resources.

Competitors of Adlai Nortye Ltd.

ONC - Price to Sales|P/S Multiple HALO (Halozyme Therapeutics, Inc.)|Revolution Medicines (RVMD) - Price to Sales|ascentage.com - P/S Multiple|Market Capitalization-to-Revenue Ratio CGON (cgoncology.com)|URGN: P/S Multiple|Bicara Therapeutics Inc (BCAX) - P/S Multiple|Price-to-Revenue Ratio personalis.com|Market Cap to Revenue Erasca Corp (ERAS)|Market Cap to Revenue DCTH (Delcath)|Price-to-Revenue Coefficient Y-mAbs Therapeutics, Inc.|P/S Multiple AURA (Aura Biosciences Inc)|Market Capitalization-to-Revenue Ratio CADL|ARAY: Market Cap to Revenue|Price-to-Revenue Coefficient sellaslifesciences.com SLS|ACTU (Actuate Therapeutics, Inc) - Market Cap to Revenue|Market Cap to Revenue Ratio CTOR|Price-to-Revenue Ratio TuHURA Biosciences Inc.|TARA: Market Capitalization-to-Revenue Ratio|Price-to-Revenue Ratio Fate Therapeutics (FATE)|Price-to-Revenue Coefficient Aadi Bioscience|Price-to-Revenue Ratio TScan Therapeutics Inc TCRX|CSBR: Market Cap to Revenue Ratio|XBIT: Market Cap to Revenue|Market Capitalization-to-Revenue Ratio CVM (cel-sci.com)|OSTX: P/S Multiple|Price to Sales Radiopharm Theranostics Ltd (RADX)|ARTV (Artiva) - P/S Multiple|P/S Multiple verupharma.com|Market Cap to Revenue TPST (tempesttx.com)|Market Cap to Revenue Xilio Therapeutics Inc XLO|P/S Multiple RENB (Enochian BioSciences)|Mural Bio - Price-to-Revenue Ratio|KAPA - Price-to-Revenue Ratio|OnKure Therapeutics (OKUR) - Market Cap to Revenue|GDTC: P/S Multiple|Price to Sales Curis Corp (CRIS)|APLM (apollomicsinc.com) - P/S Multiple|Market Cap to Revenue Tharimmune Corp (THAR)|P/S Multiple ADVB|GNPX - Price to Sales|Price-to-Revenue Ratio calidibio.com CLDI|SBFM - Market Cap to Revenue|XBIO - Price-to-Revenue Ratio|SLRX: Price-to-Revenue Ratio|Purple Biotech (PPBT) - Price-to-Revenue Ratio|AON - Market Capitalization-to-Revenue Ratio|Market Cap to Revenue BGNE|P/S Multiple Checkpoint Therapeutics Inc.|P/S Multiple ELEV|Market Cap to Revenue iCAD ICAD|P/S Multiple IKNA (Ikena Oncology, Inc.)|Market Capitalization-to-Revenue Ratio NTBL|Viracta Therapeutics, Inc. - P/S Multiple|Market Capitalization-to-Revenue Ratio MOR (MorphoSys Inc)|NAYA (NAYA Biosciences Inc) - Market Cap to Revenue|Market Cap to Revenue Ascentage Pharma Group Ltd